Lung Cancer Prediction Using Neural Network Ensemble with Histogram of Oriented Gradient Genomic Features

This paper reports an experimental comparison of artificial neural network (ANN) and support vector machine (SVM) ensembles and their “nonensemble” variants for lung cancer prediction. These machine learning classifiers were trained to predict lung cancer using samples of patient nucleotides with mutations in the epidermal growth factor receptor, Kirsten rat sarcoma viral oncogene, and tumor suppressor p53 genomes collected as biomarkers from the IGDB.NSCLC corpus. The Voss DNA encoding was used to map the nucleotide sequences of mutated and normal genomes to obtain the equivalent numerical genomic sequences for training the selected classifiers. The histogram of oriented gradient (HOG) and local binary pattern (LBP) state-of-the-art feature extraction schemes were applied to extract representative genomic features from the encoded sequences of nucleotides. The ANN ensemble and HOG best fit the training dataset of this study with an accuracy of 95.90% and mean square error of 0.0159. The result of the ANN ensemble and HOG genomic features is promising for automated screening and early detection of lung cancer. This will hopefully assist pathologists in administering targeted molecular therapy and offering counsel to early stage lung cancer patients and persons in at risk populations

Computer-Assisted Characterization of Prostate Cancer on Magnetic Resonance Imaging

Prostate cancer (PCa) is one of the most prevalent cancers among men. Early diagnosis can improve survival and reduce treatment costs. Current inter-radiologist variability for detection of PCa is high. The use of multi-parametric magnetic resonance imaging (mpMRI) with machine learning algorithms has been investigated both for improving PCa detection and for PCa diagnosis. Widespread clinical implementation of computer-assisted PCa lesion characterization remains elusive; critically needed is a model that is validated against a histologic reference standard that is densely sampled in an unbiased fashion. We address this using our technique for highly accurate fusion of mpMRI with whole-mount digitized histology of the surgical specimen. In this thesis, we present models for characterization of malignant, benign and confounding tissue and aggressiveness of PCa. Further validation on a larger dataset could enable improved characterization performance, improving survival rates and enabling a more personalized treatment plan

Deep Functional Mapping For Predicting Cancer Outcome

The effective understanding of the biological behavior and prognosis of cancer subtypes is becoming very important in-patient administration. Cancer is a diverse disorder in which a significant medical progression and diagnosis for each subtype can be observed and characterized. Computer-aided diagnosis for early detection and diagnosis of many kinds of diseases has evolved in the last decade. In this research, we address challenges associated with multi-organ disease diagnosis and recommend numerous models for enhanced analysis. We concentrate on evaluating the Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) for brain, lung, and breast scans to detect, segment, and classify types of cancer from biomedical images. Moreover, histopathological, and genomic classification of cancer prognosis has been considered for multi-organ disease diagnosis and biomarker recommendation. We considered multi-modal, multi-class classification during this study. We are proposing implementing deep learning techniques based on Convolutional Neural Network and Generative Adversarial Network. In our proposed research we plan to demonstrate ways to increase the performance of the disease diagnosis by focusing on a combined diagnosis of histology, image processing, and genomics. It has been observed that the combination of medical imaging and gene expression can effectively handle the cancer detection situation with a higher diagnostic rate rather than considering the individual disease diagnosis. This research puts forward a blockchain-based system that facilitates interpretations and enhancements pertaining to automated biomedical systems. In this scheme, a secured sharing of the biomedical images and gene expression has been established. To maintain the secured sharing of the biomedical contents in a distributed system or among the hospitals, a blockchain-based algorithm is considered that generates a secure sequence to identity a hash key. This adaptive feature enables the algorithm to use multiple data types and combines various biomedical images and text records. All data related to patients, including identity, pathological records are encrypted using private key cryptography based on blockchain architecture to maintain data privacy and secure sharing of the biomedical contents

Knowledge Driven Approaches and Machine Learning Improve the Identification of Clinically Relevant Somatic Mutations in Cancer Genomics

For cancer genomics to fully expand its utility from research discovery to clinical adoption, somatic variant detection pipelines must be optimized and standardized to ensure identification of clinically relevant mutations and to reduce laborious and error-prone post-processing steps. To address the need for improved catalogues of clinically and biologically important somatic mutations, we developed DoCM, a Database of Curated Mutations in Cancer (http://docm.info), as described in Chapter 2. DoCM is an open source, openly licensed resource to enable the cancer research community to aggregate, store and track biologically and clinically important cancer variants. DoCM is currently comprised of 1,364 variants in 132 genes across 122 cancer subtypes, based on the curation of 876 publications. To demonstrate the utility of this resource, the mutations in DoCM were used to identify variants of established significance in cancer that were missed by standard variant discovery pipelines (Chapter 3). Sequencing data from 1,833 cases across four TCGA projects were reanalyzed and 1,228 putative variants that were missed in the original TCGA reports were identified. Validation sequencing data were produced from 93 of these cases to confirm the putative variant we detected with DoCM. Here, we demonstrated that at least one functionally important variant in DoCM was recovered in 41% of cases studied. A major bottleneck in the DoCM analysis in Chapter 3 was the filtering and manual review of somatic variants. Several steps in this post-processing phase of somatic variant calling have already been automated. However, false positive filtering and manual review of variant candidates remains as a major challenge, especially in high-throughput discovery projects or in clinical cancer diagnostics. In Chapter 4, an approach that systematized and standardized the post-processing of somatic variant calls using machine learning algorithms, trained on 41,000 manually reviewed variants from 20 cancer genome projects, is outlined. The approach accurately reproduced the manual review process on hold out test samples, and accurately predicted which variants would be confirmed by orthogonal validation sequencing data. When compared to traditional manual review, this approach increased identification of clinically actionable variants by 6.2%. These chapters outline studies that result in substantial improvements in the identification and interpretation of somatic variants, the use of which can standardize and streamline cancer genomics, enabling its use at high throughput as well as clinically

Using deep learning to detect digitally encoded DNA trigger for Trojan malware in Bio‑Cyber attacks

This article uses Deep Learning technologies to safeguard DNA sequencing against Bio-Cyber attacks. We consider a hybrid attack scenario where the payload is encoded into a DNA sequence to activate a Trojan malware implanted in a software tool used in the sequencing pipeline in order to allow the perpetrators to gain control over the resources used in that pipeline during sequence analysis. The scenario considered in the paper is based on perpetrators submitting synthetically engineered DNA samples that contain digitally encoded IP address and port number of the perpetrator’s machine in the DNA. Genetic analysis of the sample’s DNA will decode the address that is used by the software Trojan malware to activate and trigger a remote connection. This approach can open up to multiple perpetrators to create connections to hijack the DNA sequencing pipeline. As a way of hiding the data, the perpetrators can avoid detection by encoding the address to maximise similarity with genuine DNAs, which we showed previously. However, in this paper we show how Deep Learning can be used to successfully detect and identify the trigger encoded data, in order to protect a DNA sequencing pipeline from Trojan attacks. The result shows nearly up to 100% accuracy in detection in such a novel Trojan attack scenario even after applying fragmentation encryption and steganography on the encoded trigger data. In addition, feasibility of designing and synthesizing encoded DNA for such Trojan payloads is validated by a wet lab experiment

Artificial intelligence in cancer imaging: Clinical challenges and applications

Judgement, as one of the core tenets of medicine, relies upon the integration of multilayered data with nuanced decision making. Cancer offers a unique context for medical decisions given not only its variegated forms with evolution of disease but also the need to take into account the individual condition of patients, their ability to receive treatment, and their responses to treatment. Challenges remain in the accurate detection, characterization, and monitoring of cancers despite improved technologies. Radiographic assessment of disease most commonly relies upon visual evaluations, the interpretations of which may be augmented by advanced computational analyses. In particular, artificial intelligence (AI) promises to make great strides in the qualitative interpretation of cancer imaging by expert clinicians, including volumetric delineation of tumors over time, extrapolation of the tumor genotype and biological course from its radiographic phenotype, prediction of clinical outcome, and assessment of the impact of disease and treatment on adjacent organs. AI may automate processes in the initial interpretation of images and shift the clinical workflow of radiographic detection, management decisions on whether or not to administer an intervention, and subsequent observation to a yet to be envisioned paradigm. Here, the authors review the current state of AI as applied to medical imaging of cancer and describe advances in 4 tumor types (lung, brain, breast, and prostate) to illustrate how common clinical problems are being addressed. Although most studies evaluating AI applications in oncology to date have not been vigorously validated for reproducibility and generalizability, the results do highlight increasingly concerted efforts in pushing AI technology to clinical use and to impact future directions in cancer care

Exploring the Intersection of Multi-Omics and Machine Learning in Cancer Research

Cancer biology and machine learning represent two seemingly disparate yet intrinsically linked fields of study. Cancer biology, with its complexities at the cellular and molecular levels, brings up a myriad of challenges. Of particular concern are the deviations in cell behaviour and rearrangements of genetic material that fuel transformation, growth, and spread of cancerous cells. Contemporary studies of cancer biology often utilise wide arrays of genomic data to pinpoint and exploit these abnormalities with an end-goal of translating them into functional therapies. Machine learning allows machines to make predictions based on the learnt data without explicit programming. It leverages patterns and inferences from large datasets, making it an invaluable tool in the modern era of large scale genomics. To this end, this doctoral thesis is underpinned by three themes: the application of machine learning, multi-omics, and cancer biology. It focuses on employment of machine learning algorithms to the tasks of cell annotation in single-cell RNA-seq datasets and drug response prediction in pre-clinical cancer models. In the first study, the author and colleagues developed a pipeline named Ikarus to differentiate between neoplastic and healthy cells within single-cell datasets, a task crucial for understanding the cellular landscape of tumours. Ikarus is designed to construct cancer cell-specific gene signatures from expert-annotated scRNA-seq datasets, score these genes, and distribute the scores to neighbouring cells via network propagation. This method successfully circumvents two common challenges in single-cell annotation: batch effects and unstable clustering. Furthermore, Ikarus utilises a multi-omic approach by incorporating CNVs inferred from scRNA-seq to enhance classification accuracy. The second study investigated how multi-omic analysis could enhance drug response prediction in pre-clinical cancer models. The research suggests that the typical practice of panel sequencing — a deep profiling of select, validated genomic features — is limited in its predictive power. However, incorporating transcriptomic features into the model significantly improves predictive ability across a variety of cancer models and is especially effective for drugs with collateral effects. This implies that the combined use of genomic and transcriptomic data has potential advantages in the pharmacogenomic arena. This dissertation recapitulates the findings of two aforementioned studies, which were published in Genome Biology and Cancers journals respectively. The two studies illustrate the application of machine learning techniques and multi-omic approaches to address conceptually distinct problems within the realm of cancer biology.Die Krebsbiologie und das maschinelle Lernen sind zwei scheinbar konträre, aber intrinsisch verbundene Forschungsbereiche. Insbesondere die Krebsbiologie ist auf zellul ̈arer und molekularer Ebene hoch komplex und stellt den Forschenden vor eine Vielzahl von Herausforderungen. Zu verstehen wie abweichendes Zellverhalten und die Umstrukturierung genetischer Komponente die Transformation, das Wachstum und die Ausbreitung von Krebszellen antreiben, ist hierbei eine besondere Herausforderung. Gleichzeitig bestrebt die Krebsbiologie diese Abnormalitäten zu nutzen zu machen, Wissen aus ihnen zu gewinnen und sie so in funktionale Therapien umzusetzen. Maschinelles Lernen ermöglicht es Vorhersagen auf der Grundlage von gelernten Daten ohne explizite Programmierung zu treffen. Es erkennt Muster in großen Datensätzen, erschließt sich so Erkenntnisse und ist deswegen ein unschätzbar wertvolles Werkzeug im modernen Zeitalter der Hochdurchsatz Genomforschung. Aus diesem Grund ist maschinelles Lernen eines der drei Haupthemen dieser Doktorarbeit, neben Multi-Omics und Krebsbiologie. Der Fokus liegt hierbei insbesondere auf dem Einsatz von maschinellen Lernalgorithmen zum Zweck der Zellannotation in Einzelzell RNA-Sequenzdatensätzen und der Vorhersage der Arzneimittelwirkung in präklinischen Krebsmodellen. In der ersten, hier präsentierten Studie, entwickelten der Autor und seine Kollegen eine Pipeline namens Ikarus. Diese kann zwischen neoplastischen und gesunden Zellen in Einzelzell-Datensätzen unterscheiden. Eine Aufgabe, die für das Verst ̈andnis der zellulären Landschaft von Tumoren entscheidend ist. Ikarus ist darauf ausgelegt, krebszellenspezifische Gensignaturen aus expertenanotierten scRNA-seq-Datensätzen zu konstruieren, diese Gene zu bewerten und die Bewertungen über Netzwerkverbreitung auf benachbarte Zellen zu verteilen. Diese Methode umgeht erfolgreich zwei häufige Herausforderungen bei der Einzelzellannotation: den Chargeneffekt und die instabile Clusterbildung. Darüber hinaus verwendet Ikarus, durch das Einbeziehen von scRNA-seq abgeleiteten CNVs, einen Multi-Omic-Ansatz der die Klassifikationsgenauigkeit verbessert. Die zweite Studie untersuchte, wie Multi-Omic-Analysen die Vorhersage der Arzneimittelwirkung in präklinischen Krebsmodellen optimieren können. Die Forschung legt nahe, dass die übliche Praxis des Panel Sequenzierens - die umfassende Profilierung ausgewählter, validierter genomischer Merkmale - in ihrer Vorhersagekraft begrenzt ist. Durch das Einbeziehen transkriptomischer Merkmale in das Modell konnte jedoch die Vorhersagefähigkeit bei verschiedenen Krebsmodellen signifikant verbessert werden, ins besondere für Arzneimittel mit Nebenwirkungen. Diese Dissertation fasst die Ergebnisse der beiden oben genannten Studien zusammen, die jeweils in Genome Biology und Cancers Journalen veröffentlicht wurden. Die beiden Studien veranschaulichen die Anwendung von maschinellem Lernen und Multi-Omic-Ansätzen zur Lösung konzeptionell unterschiedlicher Probleme im Bereich der Krebsbiologie

Bioactive Molecules from the Innate Immunity of Ascidians and Innovative Methods of Drug Discovery: A Computational Approach Based on Artificial Intelligence

The study of bioactive molecules of marine origin has created an important bridge between biological knowledge and its applications in biotechnology and biomedicine. Current studies in different research fields, such as biomedicine, aim to discover marine molecules characterized by biological activities that can be used to produce potential drugs for human use. In recent decades, increasing attention has been paid to a particular group of marine invertebrates, the Ascidians, as they are a source of bioactive products. We describe omics data and computational methods relevant to identifying the mechanisms and processes of innate immunity underlying the biosynthesis of bioactive molecules, focusing on innovative computational approaches based on Artificial Intelligence. Since there is increasing attention on finding new solutions for a sustainable supply of bioactive compounds, we propose that a possible improvement in the biodiscovery pipeline might also come from the study and utilization of marine invertebrates’ innate immunity